Skip to content

Study · Randomized controlled trial · n = 9 · 2004

4 results

Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease.

Bara-Jimenez W, Dimitrova T, Sherzai A, Favit A, Mouradian MM, Chase TN

Movement disorders : official journal of the Movement Disorder Society1 Oct 2004Cited by 37 (Europe PMC)

PMID15390018 (opens in a new tab)DOI10.1002/mds.20124 (opens in a new tab)PepBankPUB-15390018
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In advanced Parkinson disease, NS 2330 given alone or with levodopa did not change parkinsonian scores versus placebo.

    In plain wordsIn advanced Parkinson disease, NS 2330 given alone or with levodopa did not change symptom scores versus placebo.

    Peptide
    Tesofensine
    Outcome
    No significant changeParkinsonian scores
    Study

    n = 9

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    At the dose administered, no change in parkinsonian scores was found when NS 2330 was given alone or with levodopa.
    1 context sentence
    Summary · context
    This randomized, double-blind, placebo-controlled study compared the acute effects of the monoamine uptake inhibitor NS 2330 to those of placebo in 9 relatively advanced parkinsonian patients.
  2. 02HumanRandomized controlled trialSafety outcome

    In advanced Parkinson disease, adding NS 2330 to levodopa did not appear to alter levodopa-associated dyskinesia severity versus placebo.

    In plain wordsIn advanced Parkinson disease, adding NS 2330 to levodopa did not appear to change dyskinesia severity compared with placebo.

    Peptide
    Tesofensine
    Outcome
    No significant changeDyskinesia severity
    Study

    n = 9

    Comparator
    Placebo
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, NS 2330 coadministration did not appear to alter dyskinesia severity or the duration of the antiparkinsonian response to levodopa.
    1 context sentence
    Summary · context
    This randomized, double-blind, placebo-controlled study compared the acute effects of the monoamine uptake inhibitor NS 2330 to those of placebo in 9 relatively advanced parkinsonian patients.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In advanced Parkinson disease, adding NS 2330 to levodopa did not appear to alter the duration of the antiparkinsonian response to levodopa versus placebo.

    In plain wordsIn advanced Parkinson disease, adding NS 2330 to levodopa did not appear to change how long the response to levodopa lasted compared with placebo.

    Peptide
    Tesofensine
    Outcome
    No significant changeDuration of levodopa response
    Study

    n = 9

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, NS 2330 coadministration did not appear to alter dyskinesia severity or the duration of the antiparkinsonian response to levodopa.
    1 context sentence
    Summary · context
    This randomized, double-blind, placebo-controlled study compared the acute effects of the monoamine uptake inhibitor NS 2330 to those of placebo in 9 relatively advanced parkinsonian patients.
  4. 04HumanRandomized controlled trialSafety outcome

    In advanced Parkinson disease, NS 2330 was well tolerated.

    In plain wordsIn advanced Parkinson disease, participants tolerated NS 2330 well.

    Peptide
    Tesofensine
    Outcome
    Not applicableTolerability
    Study

    n = 9

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The drug was well tolerated.
    1 context sentence
    Summary · context
    This randomized, double-blind, placebo-controlled study compared the acute effects of the monoamine uptake inhibitor NS 2330 to those of placebo in 9 relatively advanced parkinsonian patients.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.